Efficacy of intestinal microorganisms on immunotherapy of non-small cell lung cancer
Loading...
Date
2024-05
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Ltd
Abstract
While the 5-year survival rate of patients with advanced non-small cell lung cancer (NSCLC) has
seen some improvement, the majority of NSCLC patients fail to respond to immunotherapy with
immune checkpoint inhibitors (ICIs). It is critical to identify effective biomarkers that can
enhance the efficacy of immunotherapy. The clinical data in the current study were collected
from NSCLC patients treated with ICIs, and two groups were classified according to treatment
effect: good group with consistent efficacy, poor group with only progressiveness. Differences in
intestinal microbiota between the two groups were analyzed using 16s rRNA sequencing. Beta
diversity analysis indicated differences between the two groups that were available for differentiation. Comparison of the number of common or unique operational taxonomic units (OTUs)
among different groups suggested that there were 53 unique OTUs in the good group and 51
unique OTUs in the poor group. At the phylum level, there was a difference between the two
groups for several bacterial groups with the highest abundance values, among which Firmicutes,
Actinobacteria and Fusobacteria were more abundant in the good group. Members of the genera
Bifidobacterium and Lactobacillus were abundant in the good group, while the abundance of
Bacteroides was low. Biomarkers in the poor group included Bacteroides, Bacteroidetes, Bacteroidia,
Bacteroidales, Bacteroidaceae and Veillonellaceae. The intestinal microbiota composition affected
the immunotherapy process for NSCLC, which might offer more rational instructions for the
clinical application of ICIs in NSCLC patients.
Description
Keywords
Non-small cell lung cancer Immunotherapy 16s rRNA Intestinal microorganisms Biomarker
Citation
Xu, Hua, Yongchun Deng, Qing Zhu, et al. 'Efficacy of Intestinal Microorganisms on Immunotherapy of Non-Small Cell Lung Cancer', Heliyon, vol. 10/no. 9, (2024), pp. e29899-e29899.